Med-Chemist : "Quintessential Medicinal Chemistry"
Showing posts with label
relapsed/refractory CLL with 17P deletion
.
Show all posts
Showing posts with label
relapsed/refractory CLL with 17P deletion
.
Show all posts
Monday, October 5, 2015
AbbVie's venetoclax Phase 2 trial meets primary endpoint in patients with relapsed/refractory CLL with 17P deletion
›
AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced that a Phase 2 trial of its investigational medicine venetocla...
Thursday, October 1, 2015
AbbVie's venetoclax Phase 2 trial meets primary endpoint in patients with relapsed/refractory CLL with 17P deletion
›
Venetoclax, also known as ABT-199 or GDC0199, is an orally bioavailable, selective small molecule inhibitor of the anti-apoptotic pr...
›
Home
View web version
